TITLE

Efficacy of certolizumab pegol: a case study in a patient with rheumatoid arthritis on maintenance hemodialysis

AUTHOR(S)
Nishimura, Akito; Minegishi, Yohjiroh; Kwamura, Keiko; Ichino, Asako; Uchiyama, Katsufumi
PUB. DATE
September 2015
SOURCE
Rheumatology International;Sep2015, Vol. 35 Issue 9, p1601
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a case study of a 63-year-old woman who was diagnosed nephritis in her twenties and had polyarticular pain in her earlier. It mentions that she was diagnosed with rheumatoid arthritis (RA). Etanercept (ETN) was administrated as prednisolone did not improve her disease activity. It informs that as the pain did not resolve the ETN treatment was switched to certolizumab pegol (CZP). It was anticipated dose impacted efficacy for improvement of RA symptoms.
ACCESSION #
108976473

 

Related Articles

  • Bedtime Single-Dose Prednisolone in Clinically Stable Rheumatoid Arthritis Patients. Bagher, Owlia Mohammad; Golbarg, Mehrpoor; Moneyreh, Modares Mosadegh // ISRN Pharmacology;2012, p1 

    Introduction. Sign and symptoms of rheumatoid arthritis have circadian rhythms and are more prominent in themorning. Timing of glucocorticoid administration may be important with respect to the natural secretion of endogenous glucocorticoids. Herein, we intended to test the hypothesis that...

  • 1H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis. Priori, Roberta; Casadei, Luca; Valerio, Mariacristina; Scrivo, Rossana; Valesini, Guido; Manetti, Cesare // PLoS ONE;11/11/2015, Vol. 10 Issue 10, p1 

    Objective: A considerable proportion of patients with rheumatoid arthritis (RA) do not have a satisfactory response to biological therapies. We investigated the use of metabolomics approach to identify biomarkers able to anticipate the response to biologics in RA patients. Methods: Due to...

  • Etanercept-Induced Pityriasis Lichenoides Chronica in a Patient with Rheumatoid Arthritis. Echeverri, Andrés F.; Vidal, Andrés; Cañas, Carlos A.; Agualimpia, Andrés; Tobón, Gabriel J.; Bonilla-Abadía, Fabio // Case Reports in Dermatological Medicine;2/18/2015, Vol. 2015, p1 

    We present a 74-year-old female patient who developed a pityriasis lichenoides chronica (PLC) during etanercept therapy. This association is not described in the literature and might be considered in the spectrum of cutaneous adverse reactions of etanercept.

  • Erratum to: Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases. Nakagomi, Daiki; Ikeda, Kei; Kawashima, Hirotoshi; Kobayashi, Yoshihisa; Suto, Akira; Nakajima, Hiroshi // Rheumatology International;Oct2013, Vol. 33 Issue 10, p2707 

    A correction to the article "Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases" which was published in the September 11, 2013 issue is presented.

  • Etanercept.  // Reactions Weekly;8/23/2008, Issue 1216, p18 

    The article describes a case involving a 44-year-old woman who developed lupus nephritis after receiving etanercept for rheumatoid arthritis. She had received etanercept twice a week for the previous 9 months. She later experienced myalgia, joint pain, headache, mouth ulcers, weakness and fever....

  • Intertoe Squamous Cell Carcinoma Developed in a Patient with Rheumatoid Arthritis under Etanercept Therapy. Rallis, Efstathios; Bournia, Vasiliki-Kalliopi; Verros, Constantinos; Iliopoulos, Alexios // Case Reports in Medicine;3/1/2015, Vol. 2015, p1 

    The use of tumor necrosis factor-α (TNF-α) inhibitors in the treatment of various inflammatory conditions has altered the field of medical therapeutics. Squamous cell carcinoma is the second most common cancer of the skin, usually affecting sun-exposed areas of the body. We present here...

  • Head-to-head study with RA drugs.  // Australian Journal of Pharmacy;Jul2013, Vol. 94 Issue 1118, p30 

    The article focuses on the study ADalimumab ACTemrA (ADACTA)", which was published in the periodical "The Lancet," reveals that Actemra offers improvement in the signs and symptoms of rheumatoid arthritis (RA) for patients who require monotherapy as compared to adalimumab, as of July 1, 2013.

  • Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Dcodhar, S. D.; Sethi, R.; Srimal, R. C. // Indian Journal of Medical Research;Jul2013, Vol. 138 Issue 1, p632 

    A short term, double blind, cross-over study was carried out in 18 patients with 'definite' rheumatoid arthritis to compare the antirheumatic activity of curcumin (diferuloyl methane) 1200 mg/day with phenylbutazone 300 mg/day. Subjective and objective assessment in patients who were not taking...

  • Methotrexate.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p195 

    An abstract of the article "Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report" by H. Shimada and others is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics